secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001193125-22-071251
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Q4/2021 net loss $16.8M; positive Phase 3 ROMAN trial, cash $71M
-----------------------------------------------------------------------

- Net loss of $16.8M ($0.64/sh) in Q4 2021 vs $20.1M ($0.80/sh) in Q4 2020; FY net loss $80.5M ($3.12/sh).
- Phase 3 ROMAN trial of avasopasem met primary endpoint (SOM incidence); plans to meet FDA in 2022 for NDA submission.
- Cash, cash equivalents & short-term investments $71.2M at Dec 31, 2021; expected runway into 2H 2023.
- Topline data from AESOP (esophagitis) and GRECO-1 (lung cancer) both expected in 1H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/0001193125-22-071251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/d310055d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-071251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer